Last updated on September 2018

Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor

Brief description of study

The aim of this study is to determine if the Investigational Medicinal Product Tedopi (OSE2101) is more effective than standard treatment in treating patients with stage IIIB NSCLC unsuitable for radiotherapy or metastatic NSCLC in second- or third-line treatment after failure of immune checkpoint-inhibitor regimens.

Clinical Study Identifier: NCT02654587

Contact Investigators or Research Sites near you

Start Over

Jatin K Desani, MD

Meridian Health
Neptune, NJ United States
  Connect »